Setting focus on treatment
and therapeutics for Haemostasis and Thrombotic diseases
, our main approach is to identify, optimize and develop highly efficient biotech-derived and small molecule leads with low risk profiles and large market opportunities.
achieve their objectives by performing a balanced risk business strategy featuring the following main directives:
- Investment in own discovery and development programs and driving them these towards clinical phases before partnering with pharmaceutical companies.
- Collaboration with the pharmaceutical industry leaders to share the investment and the rewards associated with generating market outcomes for innovative new therapies.
- External innovation through in-licensing of programs at stages of development that complement and balance our existing internal portfolio.